News Releases

Nov 01, 2022
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
Pipeline
Nov 01, 2022
Myriad Genetics Reports Third Quarter Financial Results
Financial
Oct 31, 2022
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
Corporate
Oct 26, 2022
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
Financial
Sep 28, 2022
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
Corporate
Aug 31, 2022
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
Products
Aug 25, 2022
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer
Pipeline
Aug 16, 2022
Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
Products
Aug 04, 2022
Myriad Genetics Reports Second Quarter Financial Results
Financial
Jul 28, 2022
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
Financial
Jul 19, 2022
Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022
Financial
Jul 12, 2022
Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial
Products
Jun 28, 2022
Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
Corporate
Jun 23, 2022
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Pipeline
Jun 09, 2022
Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
Corporate